21-208: DAA/TAA Vaccine for Immune Interception and Prevention in Ductal Carcinoma In Situ - 21-208
Summary
| Principal Investigator | Diego, Emilia |
|---|---|
| Title | A Clinical Study of a Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ |
| Status | Open |
| Locations |
UPMC Hillman Cancer Center at Rocco and Nancy Ortenzio Cancer Pavilion (Radiation Oncology) UPMC Hillman Cancer Center at UPMC Magee-Womens Hospital UPMC Hillman Cancer Center, Harrisburg |
| Treatment Type | Treatment |
| Applicable Disease Sites |
Breast DCIS ER+ |
| Drugs Involved |
Anastrozole Exemestane Letrozole Muc1 Vaccine Poly-ICLC |
| NCT # | NCT06218303 |
| ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT06218303 |
